Interim report
Page 1
JUBILANT PHARMOVA August 10 , 2026 BSE Limited , Floor 25 , P. J. Towers Dalal Street , Fort Mumbai - 400 001 Scrip Code : 530019 National Stock Exchange of India Limited , Exchange Plaza , Bandra - Kurla Complex , Bandra ( E ) , Mumbai - 400051 Symbol : JUBLPHARMA Sub .: Outcome of the Board Meeting held on August 10 , 2026 Ref : Regulation 33 read with Regulation 30 of SEBI ( Listing Obligations and Disclosure Requirements ) Regulations , 2015 ( " Listing Regulations " ) Dear Sirs , Pursuant to the provisions of Regulation 33 read with Regulation 30 and other applicable provisions of the Listing Regulations , we wish to inform you that the Board of Directors of the Company has , at its meeting held today i.e. on Monday , August 10 , 2026 , at 05:30 p.m. that concluded at 07:05 p.m. , has inter alia approved the unaudited Financial Results ( Standalone and Consolidated ) of the Company for the quarter ended June 30 , 2026 . Pursuant to the applicable provisions of the Listing Regulations , we enclose the following : a ) The unaudited Financial Results ( Standalone and Consolidated ) for the quarter ended June 30 , 2026 ; b ) Limited Review Report on the unaudited Financial Results ( Standalone and Consolidated ) for the said quarter . The above mentioned documents will be simultaneously posted on the Company's website at www.jubilantpharmova.com . A Jubilant Bhartia Company OUR VALUES INSPIRE CONFIDENCE N ALWAYS STRETCH Jubilant Pharmova Limited 1 - A , Sector 16 - A , Noida - 201 301 , UP , India Tel : +91 120 4361000 Fax : +91 120 4234895-96 www.jubilantpharmova.com Regd Office : Bhartiagram , Gajraula Distt . Amroha - 244 223 UP , India CIN L24116UP1978PLC004624 NURTURE INNOVATION EXCELLENT QUALITY
Page 2
You are requested to kindly take the same on record. Thanking you, Yours faithfully, For Jubilant Pharmova Limited Naresh Kapoor Company Secretary Encl: as above
Page 3
Walker Chandiok &_Co LLP Walker Chandiok & Co LLP Unit No. 02, Second Floor, BPTP Capital City, Plot No - 2B, Sector-94, Naida, Gautam Buddha Nagar - 201301 Uttar Pradesh. India T +91 120 485 5999 F +91 120 485 5902 Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Jubilant Pharmova Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Jubilant Pharmova Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results {'the Statement') of Jubilant Pharmova Limited ('the Company') for the quarter ended 30 June 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). 2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Ch81'Tered Accounlanls Offices lri AhmedaD.ad, B84"'1!Jakl~. Chandi(}arh. Chermai. Dehl"OOun. Goai, Gurugram. Hy,dt3rii,ad, Indore, Kochi, l<:alkata, Mumbai, New Delhi, Noida and Puna WalKer Chandiok 8 Co LLP is regislered with limited liability with identification number AAC ·2085 and has its registered office at L--41, Connaught Circus, Outer Circle. New Delhi, 110001, India
Page 4
Walker Chandiok &_Co LLP 4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For Walker Chandiok &.,,G, LLP Chartered Accounta9ts' Firm Registratio~ N6: 00i1·076N/N500013 ( _ , O ,-;__QLLP.., .~.k ~ \ \\ , ~ / .•.' v '"<,~ \r~,- \I- if , Ashish Gupta cs: o., {I; Partner ~.i,,71/M ,.ci' Membership No:. 504662 UDIN: 26504662TMHFBZ6243 Place: Noida Date: 10 August 2026
Page 5
Sr. No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Jubilant Pharmova Limited Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.) CIN:L24116UP1978PLC004624 Website: www.jubilantpharmova.com, Email: investors@jubl.com, Tel: +91-5924-267437 Statement of Standalone Unaudited Financial Results for the Quarter ended 30 June 2026 Quarter Ended 30June 31 March Particulars 2026 2026 (Unaudited) (Audited) CONTINUING OPERATIONS Revenue from operations a) Sales/Income from operations 671 703 b) Other operating income Total revenue from operations 671 703 Other income 1 5 Total income (1+2) 672 708 Expenses a) Employee benefits expense 283 248 b) Finance costs 9 9 c) Depreciation and amortisation expense 14 13 d) Other expenses 268 310 Total expenses 574 580 Profit before exceptional items and tax (3-4) 98 128 Exceptional items 87 Profit before tax (5-6) 98 41 Tax expense - Current tax 20 2 - Deferred tax charge/(credit) 5 (533) Total tax expense/(benefit) 25 (531) Profit for the period from continuing operations (7-8) 73 572 DISCONTINUED OPERATIONS Profit from discontinued operations Tax expense/(benefit) of discontinued operations Profit after tax from discontinued operations Profit for the period (9+10) 73 572 Other comprehensive income/(loss) A} In respect of continuing operations a) Items that will not be reclassified to profit or loss 1 1 b) Income tax relating to items that will not be reclassified to profit or loss (2) Sub total 1 (1) B} In respect of discontinued operations a) Items that will not be reclassified to profit or loss b) Income tax relating to items that will not be reclassified to profit or loss Sub total Other comprehensive income/{loss) for the period 1 (1) Total comprehensive income for the period {11+12) 74 571 Earnings per share of"' 1 each (not annualized for the quarters} (for continuing operations) Basic(,) 0.46 3.59 Diluted(,) 0.46 3.59 Earnings per share of"' 1 each (not annualized for the quarters) {for discontinued operations) Basic(,) Diluted(,) Earnings per share of"' 1 each (not annualized for the quarters) (for continuing and discontinued operations) Basic(,) 0.46 3.59 Diluted(,) 0.46 3.59 PaidHup equity share capital (face value per share"' 1) 159 159 Reserves excluding revaluation reserves (other equity) See accompanying notes to the Standalone Unaudited Financial Results ('fin million) Year Ended 30June 31 March 2025 2026 (Unaudited) (Audited) 595 2,634 1 595 2,635 7 24 602 2,659 232 1,038 30 73 15 60 260 1,109 537 2,280 65 379 87 65 292 12 46 12 47 24 93 41 199 26 43 9 (390) 17 433 58 632 (1) (1) (1) (1) (12) 4 (8) (1) (9) 57 623 0.26 1.25 0.26 1.25 0.10 2.72 0.10 2.72 0.36 3.97 0.36 3.97 159 159 22,964
Page 6
Jubilant Pharmova Limited Notes to the Standalone Unaudited Financial Results 1. These standalone unaudited financial results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. In accordance with Ind AS 108 "Operating Segments", segment information has been provided in the consolidated unaudited financial results of the Group and therefore no separate disclosure on segment information is given in these standalone unaudited financial results. 3. The figures for the preceding quarter ended 31 March 2026, as reported in these standalone unaudited financial results, are the balancing figures between audited figures in respect of the full financial year and the published year to date figures until the end of third quarter of that financial year. Also, the figures until the end of the third quarter had only been reviewed and not subjected to audit. Further, previous period figures have been regrouped/ reclassified to conform to the current period's classification. 4. The above standalone unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 10 August 2026. These results have been subjected to limited review by the Statutory Auditors of the Company. The review report of the Statutory Auditors is being filed with BSE Limited and National Stock Exchange of India Limited. For more details on standalone unaudited results, visit Investors section of our website at www.jubilantpharmova.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com. Place : New Delhi Date : 10 August 2026 For Jubilant Pharmova Limited PRIYAVRA T BHARTIA ~:~~;~ 2 ; 0~~;1? Priyavrat Bhartia Managing Director
Page 7
Walker Chandiok &_Co LLP Walker Chandiok & Co LLP Unit No. 02, Second Floor. BPTP Capital City, Plot No - 2B, Sector-94, Noida, Gautam Buddha Nagar - 201301 Uttar Pradesh , India T +91 120 485 5999 F +91 120 485 5902 Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Jubilant Pharmova Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Jubilant Pharmova Limited 1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Jubilant Pharmova Limited {'the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associate {refer Annexure 1 for the list of subsidiaries and associate included in the Statement) for the quarter ended 30 June 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). 2. This Statement. which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and fs in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements {SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. ,c:"c:<'-·' '"',~ We,~ l>9,penornieaf rocedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the'bisting Regu1a1ions, to the extent applicable. t~ ~~ \ t-!, n- \''-r- ..... .ff> '(;~.:'.: ... ,.,:r:»(I' ~A..vv- ·, Chartered Accciuatants Offices iri AAmedabad, Benga!uro, Chandig,art,, Chsnnai, Dahradun, Goa, Gurugram, Hyderabad, Indore, Koc hi, Kolata, Mumbai, Naw Delhi. Nc»da and Pune WSlker Chandiok & Co LLP is r€!gistered WJtn limited liability with identification number MC-2085 and has its regis!ered office at L-41. Connaughl Circus, Outer Circle, New Oelhi, 110001, ln~la
Page 8
\ ' Walker Chandiok &.Co LLP 4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement. prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 5. The Statement also includes the Group's share of net loss after tax and total comprehensive loss of ~ Nil for the quarter ended on 30 June 2026, in respect of an associate, based on their interim financial information, which have not been reviewed by their auditor, and have been furnished to us by the Holding Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this associate, is based solely on such unreviewed interim financial information. According to the information and explanations given to us by the management, this interim financial information is not material to the Group. Our conclusion is not modified in respect of this matter with respect ta our reliance on the financial information certified by the management of the associate Chartered Accountants Firm Registration No: 01 Gupta Partner Membership No. 504662 LP UDIN: 26 504662 M EWBRW1205 Place: Naida Date: 10 August 2026
Page 9
Walker Chandiok &._Co LLP Annexure 1 List of entities included in the Statement A) Name of Subsidiaries 1 Jubilant Pharma Limited 2 Jubilant Draximage (USA) Inc. 3 Jubilant Draximage Inc. 4 Draximage {UK) Limited 5 Jubilant Pharma Holdings Inc. 6 Jubilant Clinsys Inc. 7 Jubilant Cadista Pharmaceuticals Inc. 8 Jubilant HollisterStier LLC 9 Jubilant Pharma NV 10 Jubilant Pharmaceuticals NV 11 PSI Supply NV 12 Jubilant Biosys Limited 13 Jubilant Discovery Services LLC 14 Jubilant Clinsys Limited 15 Jubilant First Trust Healthcare Limited 16 Jubilant Draximage Limited 17 Jubilant Innovation (USA) Inc. 18 Jubilant HollisterStier Inc. 19 Draxis Pharma LLC 20 Drug Discovery and Development Solutions Limited 21 Trialstat Solutions Inc. 22 Jubilant HollisterStier General Partnership 23 Jubilant Generics Limited 24 Jubilant Pharma Australia Pty Limited 25 Jubilant Draximage Radiopharmacies Inc. 26 Jubilant Pharma SA Pty Limited 27 Jubilant Therapeutics India Limited 28 Jubilant Therapeutics Inc: 29 Jubilant Business Services Limited 30 Jubilant Episcribe LLC 31 Jubilant Pradel LLC 32 Jubilant Epipad LLC 33 Jubilant Epicore LLC 34 Jubilant Employee Welfare Trust 35 Jubilant Pharma UK Limited 36 Jubilant Biosys Innovative Research Services Pte. Limited 37 Jubilant Pharma ME FZ-LLC 38 1359773 B.C. Unlimited Liability Company 39 Jubilant Biosys France SAS 40 Jubilant Pharmaceutical Inc. (w.e.f. 30 December 2025) B) Name of Associates 1. SPV Laboratories Private Limited /'?~~ n~wable Energy XVI Private Limited (share of profiUloss not required to be considered) .::/~ \'6) I ~vv1 E t, 0 c,~ t.:• '~>,..__, ;..1-'~ "'il;zi,.co,.; ,
Page 10
Sr. No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Jubilant Pharmova Limited Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.) CIN:L24116UP1978PLC004624 Website: www.jubilantpharmova.com, Email: investors@jubl.com, Tel: +91-5924-267437 Statement of Consolidated Unaudited Financial Results for the Quarter ended 30 June 2026 Quarter Ended 30June 31 March Particulars 2026 2026 30June 2025 (Unaudited) (Audited) {Unaudited) Revenue from operations a) Sales/Income from operations 22,211 22,722 18,789 b) Other operating income 83 178 218 Total revenue from operations 22,294 22,900 19,007 Other income 199 237 120 Total income (1+2) 22,493 23,137 19,127 Expenses a) Cost of materials consumed 6,383 6,428 5,205 b) Purchases of stock-in-trade 869 845 730 c) Changes in inventories of finished goods, stock-in-trade and work-in progress 235 (140) 247 d) Employee benefits expense 7,535 7,669 5,911 e) Finance costs 542 565 490 f) Depreciation, amortisation and impairment expense 1,273 1,168 981 g) Other expenses 4,792 4,705 4,018 Total expenses 21,629 21,240 17,582 Profit before share of loss of an associate and exceptional items (3-4) 864 1,897 1,545 Share of loss of an associate (1) Profit before exceptional items and tax (5+6) 864 1,897 1,544 Exceptional items 137 Profit before tax (7-8) 864 1,760 1,544 Tax expense - Current tax 296 655 375 - Deferred tax charge/(credit) 4 (88) 144 Total tax expense 300 567 519 Profit for the period (9-10) 564 1,193 1,025 Other comprehensive income/(loss) i) a) Items that will not be reclassified to profit or loss 1 77 (4) b) Income tax relating to items that will not be reclassified to profit or loss (4) 1 ii) a) Items that will be reclassified to profit or loss (192) 2,746 414 b) Income tax relating to items that will be reclassified to profit or loss Other comprehensive (loss)/income for the period (191) 2,819 411 Total comprehensive income for the period (11+12) 373 4,012 1,436 Profit/(loss) attributable to: Owners of the Company 565 1,194 1,029 Non-controlling interest (1) (1) (4) Other comprehensive {loss)/income attributable to: Owners of the Company {191) 2,820 412 Non-controlling interest (1) (1) Total comprehensive income/{loss) attributable to: Owners of the Company 374 4,014 1,441 Non-controlling interest {1) (2) {5) Earnings per share of~ 1 each (not annualized for the quarters) Basic{~) 3.57 7.55 6.49 Diluted{~) 3.56 7.52 6.47 Paid-up equity share capital {face value per share"' 1) 158 158 158 Reserves excluding revaluation reserves {other equity) See accompanying notes to the Consolidated Unaudited Financial Results ('fin million) Year Ended 31 March 2026 {Audited) 82,250 546 82,796 660 83,456 23,203 3,131 109 27,006 2,118 4,404 16,749 76,720 6,736 (3) 6,733 592 6,141 1,607 559 2,166 3,975 64 1 5,393 5,458 9,433 3,985 {10) 5,464 (6) 9,449 {16) 25.15 25.08 158 70,770
Page 11
Jubilant Pharmova Limited Notes to the Consolidated Unaudited Financial Results Note 1: Consolidated Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter ended 30 June 2026 ('fin million} Quarter Ended Year Ended 30June 31 March 30June 31 March Sr. No. Particulars 2026 2026 2025 2026 (Unaudited) (Audited) (Unaudited) (Audited) 1 Segment revenue a. Radiopharma 10,221 9,900 8,686 36,901 b. Allergy lmmunotherapy 2,144 2,176 1,914 7,957 C. Contract Development and Manufacturing Organisation - Sterile lnjectables 5,198 5,465 3,926 18,126 d. Contract Research, Development and Manufacturing Organisation 3,258 3,348 3,114 12,649 e. Generics 1,734 2,144 1,660 7,735 f. Proprietary Novel Drugs Total 22,555 23,033 19,300 83,368 Less: Inter segment revenue 403 281 421 1,157 Total segment revenue 22,152 22,752 18,879 82,211 Add: Unallocable corporate 142 148 128 585 Total revenue from operations 22,294 22,900 19,007 82,796 2 Segment results (profit(+)/loss(-) before tax, exceptional items and interest from each segment) a. Radiopharma 780 778 986 3,599 b. Allergy !mmunotherapy 635 898 613 2,717 c. Contract Development and Manufacturing Organisation - Sterile lnjectab!es 73 559 431 2,063 d. Contract Research, Development and Manufacturing Organisation 356 360 270 1,238 e. Generics (101) 174 (4) 276 f. Proprietary Novel Drugs (76) (74) (62) (194) Total segment results 1,667 2,695 2,234 9,699 Less: i. Interest {Finance costs) 542 565 490 2,118 iL Exceptional items and unallocable expenditure (net of unallocable income) 261 370 200 1,440 Profit before tax 864 1,760 1,544 6,141 3 Segment assets a. Radiopharma 38,572 36,792 28,819 36,792 b. Allergy lmmunotherapy 6,241 6,310 5,630 6,310 C. Contract Development and Manufacturing Organisation - Sterile !njectables 63,551 60,583 50,095 60,583 d. Contract Research, Development and Manufacturing Organisation 17,669 17,727 17,238 17,727 e. Generics 11,787 12,419 12,029 12,419 f. Proprietary Novel Drugs 3,384 3,308 2,773 3,308 g. Unallocable corporate assets 18,533 18,088 13,449 18,088 Total segment assets 159,737 155,227 130,033 155,227 4 Segment liabilities a. Radiopharma 12,587 12,394 9,199 12,394 b. Allergy lmmunotherapy 1,048 1,310 784 1,310 C. Contract Development and Manufacturing Organisation - Sterile lnjectab!es 27,662 27,852 22,987 27,852 d. Contract Research, Development and Manufacturing Organisation 4,557 4,417 3,821 4,417 e. Generics 2,415 2,594 2,588 2,594 f. Proprietary Novel Drugs 139 98 120 98 g. Unallocable corporate liabilities 39,997 35,606 26,673 35,606 Total segment liabilities 88,405 84,271 66,172 84,271
Page 12
Jubilant Pharmova Limited Notes to the Consolidated Unaudited Financial Results 2. These consolidated unaudited financial results have been prepared in accordance with Indian Accounting Standards {"Ind AS") prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI {Listing Obligations and Disclosure Requirements) Regulations, 2015. 3. The figures for the preceding quarter ended 31 March 2026, as reported in these consolidated unaudited financial results, are the balancing figures between audited figures in respect of the full financial year and the published year to date figures until the end of third quarter of that financial year. Also, the figures until the end of the third quarter had only been reviewed and not subjected to audit. Further, previous period figures have been regrouped/ reclassified to conform to the current period's classification. 4. The above consolidated unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 10 August 2026. These results have been subjected to limited review by the Statutory Auditors of the Company. The review report of the Statutory Auditors is being filed with BSE Limited and National Stock Exchange of India Limited. For more details on consolidated unaudited results, visit Investors section of our website at www.jubilantpharmova.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com. Place : New Delhi Date : 10 August 2026 For Jubilant Pharmova Limited PRIYAVRA ~~;~~~;~1;~~~;,A T BHARTIA ~;%;~':0~~,~~ Priyavrat Bhartia Managing Director